# Pfizer (PFE) — Earnings

PFE · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/pfe/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 28, 2026 |
| EPS actual | $0.77 |
| EPS estimate | $0.68 |
| EPS surprise | +12.87% |
| Revenue surprise | +4.41% |
| Revenue | $15.0B |
| Revenue estimate | $14.4B |
| Reported | Aug 4, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/65773f36-ad5c-53ce-17ce-8382ad90dd51.html) |

Pfizer reported Q2 2026 results on August 4, 2026. Earnings per share came in at $0.77, ahead of the $0.68 estimate by 12.87%. Revenue was $15.0 billion, above the $14.4 billion consensus. Compared with Q2 2025, EPS slipped about 1% from $0.78, while revenue rose about 2% from $14.7 billion.

The longer record shows a sharp reset after 2022. That year, Pfizer earned $6.58 per share on $100.3 billion in revenue. Annual EPS fell to $1.83 in 2023 as revenue dropped to $58.4 billion. Q3 2023 was a loss of $0.17 per share, the only loss in the table and the only quarter that missed its estimate. Annual EPS then recovered to $3.11 in 2024 and $3.23 in 2025. The first half of 2026 adds up to $1.52, about 11% less than the same period a year earlier. Over the last 20 quarters, Pfizer beat the EPS estimate 19 times, often by wide margins.

Pfizer reported Q3 between October 29 and November 4 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue holds near $15 billion.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 4, 2026 | $0.68 | $0.77 | 12.87% | $14.4B | $15.0B |
| Q1 2026 | May 5, 2026 | $0.72 | $0.75 | 3.92% | $13.8B | $14.5B |
| Q4 2025 | Feb 3, 2026 | $0.57 | $0.66 | 16.42% | $16.8B | $17.6B |
| Q3 2025 | Nov 4, 2025 | $0.63 | $0.87 | 37.53% | $16.5B | $16.7B |
| Q2 2025 | Aug 5, 2025 | $0.58 | $0.78 | 34.39% | $13.6B | $14.7B |
| Q1 2025 | Apr 29, 2025 | $0.67 | $0.92 | 38.22% | $13.9B | $13.7B |
| Q4 2024 | Feb 4, 2025 | $0.47 | $0.63 | 33.59% | $17.4B | $17.8B |
| Q3 2024 | Oct 29, 2024 | $0.61 | $1.06 | 72.53% | $14.9B | $17.7B |
| Q2 2024 | Jul 30, 2024 | $0.46 | $0.60 | 31.03% | $13.0B | $13.3B |
| Q1 2024 | May 1, 2024 | $0.52 | $0.82 | 58.98% | $13.9B | $14.9B |
| Q4 2023 | Jan 30, 2024 | −$0.16 | $0.10 | 163.21% | $14.4B | $14.2B |
| Q3 2023 | Oct 31, 2023 | −$0.08 | −$0.17 | -113.03% | $13.3B | $13.2B |
| Q2 2023 | Aug 1, 2023 | $0.57 | $0.67 | 17.52% | $13.4B | $12.7B |
| Q1 2023 | May 2, 2023 | $0.98 | $1.23 | 24.97% | $16.6B | $18.3B |
| Q4 2022 | Jan 31, 2023 | $1.05 | $1.14 | 8.91% | $24.4B | $24.3B |
| Q3 2022 | Nov 1, 2022 | $1.39 | $1.78 | 28.30% | $21.1B | $22.6B |
| Q2 2022 | Jul 28, 2022 | $1.72 | $2.04 | 18.30% | $25.5B | $27.7B |
| Q1 2022 | May 3, 2022 | $1.49 | $1.62 | 8.48% | $24.1B | $25.7B |
| Q4 2021 | Feb 8, 2022 | $0.87 | $1.08 | 23.54% | $24.2B | $23.8B |
| Q3 2021 | Nov 2, 2021 | $1.08 | $1.34 | 24.43% | $22.6B | $24.1B |

## Frequently Asked Questions

### When did Pfizer (PFE) last report earnings?

Pfizer last reported on Aug 4, 2026, covering fiscal Q2 2026.

### Did PFE beat earnings estimates?

Yes. Pfizer reported EPS of $0.77 for Q2 2026 against a $0.68 estimate — a 12.87% beat.

### How much revenue did PFE report last quarter?

Pfizer reported $15.0B in revenue for Q2 2026, against a consensus estimate of $14.4B.

## Similar Stocks

- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [MRK](https://www.lighthorse.io/tickers/mrk) — Merck & Company, Inc. Common Stock (new)
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [NVAX](https://www.lighthorse.io/tickers/nvax) — Novavax, Inc. - Common Stock
- [LLY](https://www.lighthorse.io/tickers/lly) — Eli Lilly and Company Common Stock
- [ABBV](https://www.lighthorse.io/tickers/abbv) — AbbVie Inc. Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [BMY](https://www.lighthorse.io/tickers/bmy) — Bristol-Myers Squibb Company Common Stock
- [AMGN](https://www.lighthorse.io/tickers/amgn) — Amgen Inc. - Common Stock
- [GILD](https://www.lighthorse.io/tickers/gild) — Gilead Sciences, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).